Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis (original) (raw)

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
  Article PubMed Google Scholar
• Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380(9842):680–8.
  Article CAS PubMed Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61.
  Article PubMed Google Scholar
• Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res. 2002;3:3.
  Article PubMed Central PubMed Google Scholar
• Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014;190(8):867–78.
  Article CAS PubMed Google Scholar
• Boehringer Ingelheim. Ofev® (nintedanib) capsules for oral use: US prescribing information. 2014. http://www.fda.gov/. Accessed 13 May 2015.
• European Medicines Agency. Ofev (nintedanib) soft capsules: EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 13 May 2015.
• Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58(3):1053–63.
  Article CAS PubMed Google Scholar
• European Medicines Agency. Vargatef (nintedanib) soft capsules: EU summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 13 May 2015.
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.
  Article CAS PubMed Google Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–20.
  Article PubMed Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–45.
  Article CAS PubMed Central PubMed Google Scholar
• Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15(1):157.
  Article PubMed Central PubMed Google Scholar
• Wollin L, Ostermann A, Wex E, et al. Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis [abstract]. Am J Respir Crit Care Med. 2014;189:A2008.
  Google Scholar
• Herrmann F, Wollin L. Nintedanib prevents IL-1β-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors [abstract no. P3501]. In: European Respiratory Society Congress. 2014.
• Hostettler KE, Papakonstantinou E, Zhong J, et al. Nintedanib (BIBF 1120) prevents TGF-β-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis [abstract no. P746]. In: European Respiratory Society Congress. 2014.
• Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs. 2013;31(5):1283–93.
  Article CAS PubMed Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1382–92.
  Article CAS PubMed Google Scholar
• Stopfer P, Rathgen K, Liesener A. Pharmacokinetics of BIBF 1120 after administration of single doses of 100 mg [14C]-BIBF 1120 [abstract no. 478P]. Ann Oncol. 2008;19(Suppl 8):viii158.
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87.
  Article CAS PubMed Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
  Article PubMed Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy and safety of nintedanib in patients with IPF beyond week 52: data from the phase II TOMORROW trial [abstract]. In: American Thoracic Society 2015 International Conference. 2015.
• Cottin V, Taniguchi H, Collard HR, et al. Reduction in disease progression with nintedanib in the INPULSIS™ trials [abstract plus poster]. Eur Respir J. 2014;44(Suppl 58):A1906.
  Google Scholar
• Costabel U, Richeldi L, Azuma A, et al. Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis [abstract]. In: 18th International Colloquium on Lung and Airway Fibrosis. 2014.
• Costabel U, Inoue Y, Richeldi L, et al. Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS™ trials [abstract plus poster]. Eur Respir J. 2014;44(Suppl 58):A1907.
  Google Scholar
• Taniguchi H, Xu Z, Azuma A, et al. Subgroup analysis of Asian patients in the Inpulsis™ trials of nintedanib in idiopathic pulmonary fibrosis [abstract no. O-I-007]. Respirology. 2014;19(Suppl 3):30.
  Google Scholar
• Kolb M, Richeldi L, Kimura T, et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials [abstract]. In: American Thoracic Society 2015 International Conference. 2015.
• Kolb M, Inoue Y, Costabel U, et al. Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials [abstract]. In: 18th International Colloquium on Lung and Airway Fibrosis. 2014.
• Cottin V, Taniguchi H, Richeldi L, et al. Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials [abstract]. In: 18th International Colloquium on Lung and Airway Fibrosis. 2014.
• Raghu G, Wells A, Nicholson AG, et al. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in IPF [abstract]. In: American Thoracic Society 2015 International Conference. 2015.
• Kirsten A-M, Richeldi L, Roman J, et al. Pooled analysis of mortality data from the TOMORROW and INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis (IPF) [poster]. In: 99th Annual Meeting of the German Society for Pathology. 2015.
• Crestani B, Ogura T, Pelling K, et al. Safety and tolerability of nintedanib in patients with IPF: interim analysis from an open-label extension of the INPULSIS® trials (INPULSIS®-ON) [abstract]. In: American Thoracic Society 2015 International Conference. 2015.
• Ryerson CJ, Collard HR. Hot off the breath: a big step forward for idiopathic pulmonary fibrosis. Thorax. 2014;69(9):791–2.
  Article PubMed Google Scholar
• Boehringer Ingelheim. Boehringer Ingelheim welcomes the update of the ATS/ERS/JRS/ALAT 2011 evidence based guidelines for treatment of idiopathic pulmonary fibrosis (IPF), suggesting nintedanib for the treatment of IPF [media release]. 2015. www.boehringer-ingelheim.com. Accessed 27 May 2015.
• Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med. 2014;20(5):463–71.
  Article PubMed Central PubMed Google Scholar
• Crooks MG, Hart SP. A new era of drug therapy for idiopathic pulmonary fibrosis. Lancet Respir Med. 2014;2(12):964–6.
  Article PubMed Google Scholar
• Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis: FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189–91.
  Article PubMed Google Scholar
• Ryerson CJ, Collard HR. Acute exacerbations complicating interstitial lung disease. Curr Opin Pulm Med. 2014;20(5):436–41.
  Article PubMed Google Scholar
• Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2142–3.
  Article CAS PubMed Google Scholar
• InterMune Inc. Esbriet® (pirfenidone) capsules: US prescribing information. 2014. http://www.esbriet.com/. Accessed 13 May 2015.
• European Medicines Agency. Esbriet (pifenidone) hard capsules: EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 13 May 2015.
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.
  Article CAS PubMed Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
  Article PubMed Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–9.
  Article CAS PubMed Google Scholar
• Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–91.
  Article CAS PubMed Central PubMed Google Scholar
• Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014;2(11):933–42.
  Article PubMed Google Scholar